334 related articles for article (PubMed ID: 23040224)
21. Sparing bilateral neck level IB in oropharyngeal carcinoma and xerostomia outcomes.
Tam M; Riaz N; Kannarunimit D; Peña AP; Schupak KD; Gelblum DY; Wolden SL; Rao S; Lee NY
Am J Clin Oncol; 2015 Aug; 38(4):343-7. PubMed ID: 26208401
[TBL] [Abstract][Full Text] [Related]
22. Dosimetric Predictors of Patient-Reported Xerostomia and Dysphagia With Deintensified Chemoradiation Therapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
Chera BS; Fried D; Price A; Amdur RJ; Mendenhall W; Lu C; Das S; Sheets N; Marks L; Mavroidis P
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1022-1027. PubMed ID: 28721884
[TBL] [Abstract][Full Text] [Related]
23. Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation.
Samuels SE; Tao Y; Lyden T; Haxer M; Spector M; Malloy KM; Prince ME; Bradford CR; Worden FP; Schipper M; Eisbruch A
Oral Oncol; 2016 Mar; 54():68-74. PubMed ID: 26776757
[TBL] [Abstract][Full Text] [Related]
24. A Model-Based Approach to Predict Short-Term Toxicity Benefits With Proton Therapy for Oropharyngeal Cancer.
Rwigema JM; Langendijk JA; Paul van der Laan H; Lukens JN; Swisher-McClure SD; Lin A
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):553-562. PubMed ID: 30625409
[TBL] [Abstract][Full Text] [Related]
25. Sparing all salivary glands with IMRT for head and neck cancer: Longitudinal study of patient-reported xerostomia and head-and-neck quality of life.
Hawkins PG; Lee JY; Mao Y; Li P; Green M; Worden FP; Swiecicki PL; Mierzwa ML; Spector ME; Schipper MJ; Eisbruch A
Radiother Oncol; 2018 Jan; 126(1):68-74. PubMed ID: 28823405
[TBL] [Abstract][Full Text] [Related]
26. Prospective functional outcomes in sequential population based cohorts of stage III/ IV oropharyngeal carcinoma patients treated with 3D conformal vs. intensity modulated radiotherapy.
Kerr P; Myers CL; Butler J; Alessa M; Lambert P; Cooke AL
J Otolaryngol Head Neck Surg; 2015 May; 44(1):17. PubMed ID: 25964113
[TBL] [Abstract][Full Text] [Related]
27. IMRT for head and neck cancer: reducing xerostomia and dysphagia.
Wang X; Eisbruch A
J Radiat Res; 2016 Aug; 57 Suppl 1(Suppl 1):i69-i75. PubMed ID: 27538846
[TBL] [Abstract][Full Text] [Related]
28. Helical intensity-modulated radiotherapy with concurrent chemotherapy for oropharyngeal squamous cell carcinoma: A prospective investigation of acute swallowing and toxicity patterns.
Moroney LB; Helios J; Ward EC; Crombie J; Pelecanos A; Burns CL; Spurgin AL; Blake C; Kenny L; Chua B; Hughes BGM
Head Neck; 2018 Sep; 40(9):1955-1966. PubMed ID: 29756244
[TBL] [Abstract][Full Text] [Related]
29. [Impact of neck dissection in N2-3 oropharyngeal squamous cell carcinomas treated with definitive chemoradiotherapy: An observational real-life study].
Klausner G; Troussier I; Kreps S; Fabiano E; Laccourreye O; Giraud P
Cancer Radiother; 2021 Dec; 25(8):771-778. PubMed ID: 34175226
[TBL] [Abstract][Full Text] [Related]
30. A Quantitative Clinical Decision-Support Strategy Identifying Which Patients With Oropharyngeal Head and Neck Cancer May Benefit the Most From Proton Radiation Therapy.
Brodin NP; Kabarriti R; Pankuch M; Schechter CB; Gondi V; Kalnicki S; Guha C; Garg MK; Tomé WA
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):540-552. PubMed ID: 30496877
[TBL] [Abstract][Full Text] [Related]
31. Patient-reported outcomes following parotid-sparing intensity-modulated radiotherapy for head and neck cancer. How important is dysphagia?
Roe JW; Drinnan MJ; Carding PN; Harrington KJ; Nutting CM
Oral Oncol; 2014 Dec; 50(12):1182-7. PubMed ID: 25448227
[TBL] [Abstract][Full Text] [Related]
32. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.
Chao KS; Deasy JO; Markman J; Haynie J; Perez CA; Purdy JA; Low DA
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):907-16. PubMed ID: 11240231
[TBL] [Abstract][Full Text] [Related]
33. Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer.
Orlandi E; Miceli R; Infante G; Mirabile A; Alterio D; Cossu Rocca M; Denaro N; Vigna-Taglianti R; Merlotti A; Schindler A; Pizzorni N; Fallai C; Licitra L; Bossi P
Dysphagia; 2019 Feb; 34(1):52-62. PubMed ID: 29948260
[TBL] [Abstract][Full Text] [Related]
34. Influence of radiation dose to pharyngeal constrictor muscles on late dysphagia and quality of life in patients with locally advanced oropharyngeal carcinoma.
Mogadas S; Busch CJ; Pflug C; Hanken H; Krüll A; Petersen C; Tribius S
Strahlenther Onkol; 2020 Jun; 196(6):522-529. PubMed ID: 32006068
[TBL] [Abstract][Full Text] [Related]
35. Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy.
Schwartz DL; Hutcheson K; Barringer D; Tucker SL; Kies M; Holsinger FC; Ang KK; Morrison WH; Rosenthal DI; Garden AS; Dong L; Lewin JS
Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1356-65. PubMed ID: 20646872
[TBL] [Abstract][Full Text] [Related]
36. DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.
Petkar I; Rooney K; Roe JW; Patterson JM; Bernstein D; Tyler JM; Emson MA; Morden JP; Mertens K; Miles E; Beasley M; Roques T; Bhide SA; Newbold KL; Harrington KJ; Hall E; Nutting CM
BMC Cancer; 2016 Oct; 16(1):770. PubMed ID: 27716125
[TBL] [Abstract][Full Text] [Related]
37. Reduced radiation-induced toxicity by using proton therapy for the treatment of oropharyngeal cancer.
Meijer TWH; Scandurra D; Langendijk JA
Br J Radiol; 2020 Mar; 93(1107):20190955. PubMed ID: 31971818
[TBL] [Abstract][Full Text] [Related]
38. Long-term quality of life & functional outcomes after treatment of oropharyngeal cancer.
Scott SI; Kathrine Ø Madsen A; Rubek N; Charabi BW; Wessel I; Fredslund Hadjú S; Jensen CV; Stephen S; Patterson JM; Friborg J; Hutcheson KA; Kehlet H; von Buchwald C
Cancer Med; 2021 Jan; 10(2):483-495. PubMed ID: 33277795
[TBL] [Abstract][Full Text] [Related]
39. High-dose and extended-field intensity modulated radiation therapy for early-stage NK/T-cell lymphoma of Waldeyer's ring: dosimetric analysis and clinical outcome.
Bi XW; Li YX; Fang H; Jin J; Wang WH; Wang SL; Liu YP; Song YW; Ren H; Dai JR
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1086-93. PubMed ID: 24120822
[TBL] [Abstract][Full Text] [Related]
40. Intensity-modulated radiotherapy followed by a brachytherapy boost for oropharyngeal cancer.
Al-Mamgani A; Levendag PC; van Rooij P; Meeuwis CA; Sewnaik A; Teguh DN
Head Neck; 2013 Dec; 35(12):1689-97. PubMed ID: 23483648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
